-
EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment
•
Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), the German pharmaceutical company announced last week. ATTR-CM and the Impact of AcoramidisATTR-CM is a rare disease…
-
LianBio Secures Clinical Supply Agreement with AstraZeneca for SHP2 Inhibitor Trial
•
Sino-US biotech firm LianBio (OTCMKTS: LIANY) has announced the signing of a clinical supply agreement with UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN). The agreement facilitates LianBio’s plan to test the combination of its pipeline SHP2 inhibitor, BBP-398, with AstraZeneca’s Tagrisso (osimertinib) in a Phase I clinical trial for patients…
-
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
•
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its pipeline drug candidate 3D185. The designation was granted for the drug’s potential use in treating gastric cancer and gastroesophageal junction carcinoma (GC/GEJ). This marks the…
